Alzheimer's disease (AD) is characterized by the deposition of beta- amyloid (Abeta) into senile plaque, the formation of neurofibrillary tangles, and neuronal death. The Abeta protein, a 39 to 42/43 amino acid peptide is derived from the processing of the amyloid precursor protein (APP) by beta- and gamma- secretases. There are three known pathways of Abeta generation: a lysosomal/endosomal pathway, a trans-Golgi network pathway that generates mainly extracellular Abeta/1-40, and a endoplasmic reticulum/intermediate compartment pathway that results in the accumulation of intracellular Abeta/1-42. In contrast, APP processed by an alpha-secretase produces only a large secreted non-amyloidogenic derivative (APP-S/alpha). Physiological stimuli, such as muscarinic agonists and glutamate, increase the secretion of APP-S/alpha and decrease extracellular Abeta production, suggesting that pharmacological manipulation of this pathway may be of potential therapeutic benefit to decreased the beta-amyloid load. The long-term goals of this project are to understand in detail the molecular mechanisms involved in APP-S/alpha secretion from NT2N neurons, and their impact on intracellular and extracellular Abeta production. The signaling mechanisms involved in glutamate-induced APP-S/alpha secretion are poorly understood. Our preliminary studies show the presence of metabotropic glutamate receptors in NT2N cells. Glutamate stimulation of NT2N neurons causes an increase in intracellular calcium, activation of protein kinase C, and an increase in APP-S/alpha secretion appears to require ionotropic and metabotropic receptors, although the precise contribution of each receptor-associated signal transduction pathway in unclear. Furthermore, increasing intracellular calcium and/or activating protein kinase C with phorbol esters stimulates APP-S/alpha secretion. Based on our preliminary data, the hypothesis to be tested is that activation of protein kinase C mediates metabotropic glutamate-induced APP-S/alpha secretion, while calcium sensing by synaptotagmin mediates APP-S/alpha secretion induced by increased in intracellular calcium. The general strategy used, to dissect the components of the signaling pathways regulating APP-S/alpha secretion, is to express each potential component of the signaling pathway (glutamate receptor isotype, active or inactive protein kinase C isoform, active or inactive kinase substrate, active or inactive synaptotagmin) in NT2N neurons and measure APP-S/alpha secretion and intracellular and extracellular Abeta production.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011542-08
Application #
6340628
Study Section
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$240,592
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Hurtado, David E; Molina-Porcel, Laura; Carroll, Jenna C et al. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32:7392-402
Xu, Shaohua; Brunden, Kurt R; Trojanowski, John Q et al. (2010) Characterization of tau fibrillization in vitro. Alzheimers Dement 6:110-7
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Hurtado, David E; Molina-Porcel, Laura; Iba, Michiyo et al. (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-88
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Chen, Xiao-Han; Johnson, Victoria E; Uryu, Kunihiro et al. (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214-23
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Shineman, Diana W; Dain, Aleksandra S; Kim, Minkyu L et al. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48:3787-94
Kim, Minkyu L; Zhang, Bin; Mills, Ian P et al. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28:12052-61

Showing the most recent 10 out of 94 publications